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Abstract
Background
The risk of venous thromboembolism (VTE) can be reduced by appropriate use of anticoag-
ulant prophylaxis. VTE prophylaxis does, however, remain substantially underused, particu-
larly among acutely ill medical inpatients. We sought to evaluate the clinical and economic
impact of increasing use of American College of Chest Physicians (ACCP)-recommended
VTE prophylaxis among medical inpatients from a US healthcare system perspective.
Methods and Findings
In this retrospective database cost-effectiveness evaluation, a decision-tree model was de-
veloped to estimate deaths within 30 days of admission and outcomes attributable to VTE
that might have been averted by use of low-molecular-weight heparin (LMWH) or unfractio-
nated heparin (UFH). Incremental cost-effectiveness ratio was calculated using “no prophy-
laxis” as the comparator. Data from the ENDORSE US medical inpatients and the US
nationwide Inpatient Sample (NIS) were used to estimate the annual number of eligible in-
patients who failed to receive ACCP-recommended VTE prophylaxis. The cost-
effectiveness analysis indicated that VTE-prevention strategies would reduce deaths by
0.5% and 0.3%, comparing LMWH and UFH strategies with no prophylaxis, translating into
savings of $50,637 and $25,714, respectively, per death averted. The ENDORSE findings
indicated that 51.1% of US medical inpatients were at ACCP-defined VTE risk, 47.5% of
whom received ACCP-recommended prophylaxis. By extrapolating these findings to the
NIS and applying cost-effectives analysis results, the full implementation of ACCP guide-
lines would reduce number of deaths (by 15,875 if using LMWH or 10,201 if using UFH),
and was extrapolated to calculate the cost reduction of $803M for LMWH and $262M for
UFH.
Conclusions
Efforts to improve VTE prophylaxis use in acutely ill inpatients are warranted due to the po-
tential for reducing VTE-attributable deaths, with net cost savings to healthcare systems.
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Introduction
Venous thromboembolism (VTE), comprising the conditions of deep vein thrombosis (DVT)
and pulmonary embolism (PE), is associated with considerable long-term morbidity, function-
al disability and mortality [1]. VTE is estimated to be the third most common cardiovascular
disorder, after the acute coronary syndromes and ischemic stroke [2]. Hospitalized patients are
at particularly high risk for developing VTE [1], with 5–10% of all deaths among hospitalized
patients associated with PE [3, 4]. Non-surgical patients account for 70–80% of all fatal and
50–70% of symptomatic thromboembolic events [4–7]. In addition to the clinical impact of
VTE, the economic burden of this disease is considerable [8, 9]. Direct medical costs for the
treatment of patients with nonfatal VTE are estimated to be between 6 and 8 billion dollars
based on 2004 provider payments in the United States (US) [9, 10].
Numerous randomized trials have demonstrated that the risk of VTE can be reduced in pa-
tients who receive anticoagulant prophylaxis [6, 7]. Despite evidence-based guidelines recom-
mending prophylaxis for at-risk patients [6, 7], the Epidemiologic International Day for the
Evaluation of Patients at Risk for Venous Thromboembolism in the Acute Hospital Care Set-
ting (ENDORSE) study found that VTE prophylaxis remains substantially underused, particu-
larly among acutely ill medical inpatients [11]. Presumptive reasons for this underuse include
concerns related to the cost of prophylaxis, low patient compliance with self-injectable out-of-
hospital medications, and physician concerns over possible bleeding complications or develop-
ment of heparin-induced thrombocytopenia (HIT), particularly among patients who receive
unfractionated heparin (UFH) [12]. The world faces increasing pressure to contain the costs of
healthcare; and studies measuring the cost-effectiveness of VTE prevention are becoming in-
creasingly important for gathering data to support evidence-based decisions.
In this analysis, we evaluate the potential economic impact of ongoing efforts to increase
physician adherence to American College of Chest Physicians (ACCP)-recommended guide-
lines on VTE prophylaxis, along with the estimated benefits of reducing VTE-attributable
events, among hospitalized acutely ill medical patients from a US healthcare system perspec-
tive. In addition, we evaluate the incremental cost-effectiveness ratios (ICERs) of the additional
cost for ACCP-recommended VTE prophylaxis per episode of VTE-attributable death averted
(versus no prophylaxis) among medical inpatients at ACCP-defined moderate or high VTE
risk in the US acute care hospital setting.
Methods
Ethics
The ENDORSE study was approved by the institutional review committee at UMass Medical
School. Signed patient consent was required in Brazil, Greece, and Hungary. Patient informa-
tion was anonymized and de-identified prior to analysis.
Study Design
The ENDORSE study was an observational, cross-sectional study conducted between August
2006 and January 2007. A total of 358 hospitals were selected at random from authoritative
lists of acute care hospitals (American Hospital Association List for US) in 32 participating
countries. The study was designed to assess the number of patients at moderate or high risk for
VTE in the acute care hospital setting and to determine the proportion of these at-risk patients
who received prophylaxis as recommended by the (then current) 2004 ACCP evidence-based
consensus guidelines [6]. Patient data were collected from a review of hospital charts and re-
corded in case report forms by trained data abstractors. The full methods for the ENDORSE
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study have been published [11]. In this analysis, we focused on the ENDORSE US medical in-
patients, combined with publically available US data from the Nationwide Inpatient Sample
(NIS) [13], to estimate the total annual number of medical inpatients at ACCP-defined VTE
risk and the proportion of at-risk patients who fail to receive ACCP-recommended VTE pro-
phylaxis. The NIS data is the largest all-payer inpatient care database that is publicly available
in the US, containing data from approximately 8 million hospital stays in about 1000 hospitals
sampled to approximate a 20% stratified sample of US community hospitals, and weighted to
produce national estimates [13]. Inpatient stay records in the NIS include clinical and resource
use information typically available from discharge abstracts [13]. The proportion of patients at
clinically recognized bleeding risk (i.e. contraindication to anticoagulation) was estimated
based on a previous study [14].
To match the ENDORSE study criteria, the total annual discharges of medical inpatients in
the NIS 2006 database was defined as patients who did not go to the operating room, were aged
40 years, and had a length of hospital stay2 days. The algorithm developed by Anderson
et al [15], according to the primary, secondary, and tertiary discharge diagnostic codes of the
ACCP guideline criteria (heart failure, respiratory failure, sepsis, pneumonia, cancer, stroke,
acute myocardial infarction, nonsurgical trauma, arthropathy/spondylopathy, paralysis/coma),
was used to identify medical inpatients at ACCP-defined VTE risk in the NIS database.
Decision Analysis Model
A decision-tree model was developed based on a model published by McGarry et al, with up-
dated cost estimates (Table 1 and Table 2; S1 Fig.) [16–51]. This model estimated deaths within
30 days of hospital admission attributable to VTE that might have been averted by the use of
ACCP-recommended VTE prophylaxis among a hypothetical cohort of 10,000 acutely ill med-
ical inpatients at ACCP-defined VTE risk. The present comparison of prophylaxis strategies
was based on: 1) enoxaparin, a representative low-molecular-weight heparin (LMWH), 40 mg,
administered subcutaneously once daily for 7 days; 2) unfractionated heparin (UFH), 5000 IU,
administered subcutaneously twice daily for 7 days; and 3) no prophylaxis.
The starting point of the decision-tree model was admission to an acute-care hospital due to
a serious medical condition. If patients received LMWH or UFH, the drug-related adverse
events (minor/major bleeds and symptomatic/asymptomatic HIT) were considered. Major
bleeds and symptomatic HIT may lead to death. If patients survived drug-related adverse
events, for simplicity, we assumed that they were not at risk of additional adverse events or
VTE. Conversely, patients who did not experience HIT or bleeds were considered to be at risk
of VTE. Although asymptomatic (venographically confirmed) DVT and fatal PE are generally
accepted to represent a continuum, with a common pathological cause [52, 53], we considered
the probability of true positive and false negative clinical diagnosis of DVT based on estimates
derived from studies examining the prevalence of DVT in asymptomatic patients [39, 40]. Pa-
tients with a positive clinical diagnosis (confirmed on ultrasound, computed tomography or
ventilation-perfusion scan) were presumed to be referred for VTE treatment. Different proba-
bilities of getting PE after an episode of DVT with/without treatment were used in our deci-
sion-tree model. Patients with PE who survived the critical period immediately after the acute
event (no sudden death) were divided into diagnosed or undiagnosed groups. Different PE-at-
tributed case fatality rates were used based on different clinical scenarios (sudden death, with
treatment, without treatment). The risk of death due to either drug-related adverse events or
the underlying medical condition was taken as an endpoint in our decision-tree model as well
(S1 Fig.).
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Estimates of Effectiveness. Estimates of effectiveness, including those related to efficacy
in preventing VTE or to drug-related adverse events, were based on the published literature
(Table 1). The Prophylaxis in Medical Patients with Enoxaparin (MEDENOX) study [19] was
used to estimate the risk of VTE with enoxaparin prophylaxis and the baseline risk of VTE
among untreated patients. The results of a meta-analysis by Mismetti et al [18] were used to es-
timate the risk of prophylaxis failure among patients receiving UFH.
Table 1. Probability of incident VTE and AEs within 30 days of hospital admission.
LMWH (Enoxaparin 40 mg qd) UFH (5000 IU bid) None Ref(s)
Efﬁcacy of prophylaxis
P(DVT) 0.055 0.066 0.142 [18, 19]
Safety of prophylaxis
P(bleed) 0.031 0.058 0.020 [19–22]
P(HIT) 0.001 0.010 0.000 [19–21, 23]
Consequences of AEs
P(major bleed|bleed) 0.185 0.185 0.185 [19–22, 24]
P(death|major bleed) 0.148 0.148 0.148 [25]
P(symptomatic HIT|HIT) 0.543 0.543 0.543 [19, 23, 26–28]
P(death|symptomatic HIT) 0.098 0.098 0.098 [29]
Efﬁcacy and safety of DVT treatment
P(bleed|DVT treatment) 0.083 0.083 0.083 [30, 31]
P(HIT|DVT treatment) 0.012 0.012 0.012 [30, 31]
P(PE|DVT treatment, DVT) 0.018 0.018 0.018 [30, 31]
Efﬁcacy and safety of PE treatment
P(death|PE treatment, +PE) 0.015 0.015 0.015 [32]
P(death|PE treatment, −PE) 0.003 0.003 0.003 [33]
Natural history
P(sudden death|PE) 0.100 0.100 0.100 [34, 35]
P(PE|no DVT treatment, DVT) 0.511 0.511 0.511 [36, 37]
P(death|no PE tx treatment PE) 0.260 0.260 0.260 [38]
P(death|underlying illness) 0.100 0.100 0.100 Assumption
Diagnosis of DVT
P(+clinical diagnosis|+DVT) 0.657 0.657 0.657 [39, 40]
P(−clinical diagnosis|−DVT) 0.869 0.869 0.869 [39, 40]
P(+ultrasound|+DVT) 0.960 0.960 0.960 [41–43]
P(−ultrasound|−DVT) 0.962 0.962 0.962 [41–43]
Diagnosis of PE
P(+clinical diagnosis|+PE) 0.291 0.291 0.291 [37, 44–49]
P(−clinical diagnosis|−PE) 0.910 0.910 0.910 [44]
P(+CT scan|+PE) 0.760 0.760 0.760 [49–51]
P(−CT scan|−PE) 0.894 0.894 0.894 [49–51]
P(+V/Q scan|+PE) 0.410 0.410 0.410 [44]
P(−V/Q scan|−PE) 0.970 0.970 0.970 [44]
P(+scan (average)|+PE) 0.585 0.585 0.585 Av. of CT and V/Q scans
P(−scan (average)|−PE) 0.932 0.932 0.932 Av. of CT and V/Q scans
AE, adverse event; Av., average; bid, twice daily; CT, computed tomography; DVT, deep vein thrombosis; HIT, heparin-induced thrombocytopenia; IU,
international units; LMWH, low-molecular-weight heparin; P, probability; PE, pulmonary embolism; qd, once daily; UFH, unfractionated heparin; VTE,
venous thromboembolism; V/Q, ventilation-perfusion.
doi:10.1371/journal.pone.0121429.t001
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Cost Estimates. The economic evaluation of specific ACCP-recommended prophylaxis
strategies (LMWH or UFH) relative to no prophylaxis from the US healthcare system perspec-
tive was undertaken using publicly available data, which included US wholesale prices for med-
ication costs, and Medicare reimbursement rates by diagnosis-related group for treatment
costs, as well as costs associated with the diagnosis and treatment of adverse events (Table 2).
Costs were analyzed based on direct medical costs from a US healthcare system perspective
and were adjusted to 2013 US$ by using the medical-care component of the US Consumer
Price Index [54]. Because the time horizon in this analysis is short, discounting was
not required.
Statistical Analysis
The primary outcome measure was the number of VTE-attributable deaths averted. Incremen-
tal costs, VTE-attributable deaths averted, and ICERs were calculated by comparison with no
prophylaxis. In addition, we included the estimated costs and number of deaths averted associ-
ated with each 1% improvement in adherence to ACCP prophylaxis among medical inpatients
at ACCP-defined VTE risk in the US acute care hospital setting. First, we estimated the cost
and effectiveness for each type of ACCP-recommended prophylaxis provided to medical inpa-
tients at VTE risk compared with no prophylaxis. Second, we applied this result to the entire
US medical inpatient population at ACCP-defined VTE risk to estimate the US-wide implica-
tions of the primary outcome measure.
Considering the uncertainty of the probability of developing PE after an episode of DVT
without treatment and the case-fatality rates among patients with PE that could impact on clin-
ical outcomes, we conducted one-way sensitivity analyses to determine the threshold value of
these estimates when the prophylaxis strategies begin to be effective. In addition, to estimate
the total impact of the uncertainty of all parameters on our decision-tree model, we conducted
probabilistic sensitivity analyses using Monte Carlo simulations (10,000 iterations) with β dis-
tributions for binomial variables and γ distribution for cost data.[55] Furthermore, we tested
the robustness of the results by using the interquartile range (IQR) rates of medical inpatients
at ACCP-defined VTE risk from each of the US sites in the ENDORSE study based on the
base-case scenario of the decision-tree model.
Table 2. Costs (2013 US$) associated with diagnosis and treatment of venous thromboembolism and
treatment-related adverse events.
Model variables 2013 US$ Reference
Major bleed 10,717 Deitelzweig et al, 2008 [16]
Minor bleed 5466 Deitelzweig et al, 2008 [16]
Asymptomatic HIT 1064 McGarry et al, 200 4[17]
Symptomatic HIT 14,032 McGarry et al, 2004 [17]
Treated deep vein thrombosis 10,758 Deitelzweig et al, 2008 [16]
Treated pulmonary embolism 19,032 Deitelzweig et al, 2008 [16]
Deep vein thrombosis diagnosis 449 Deitelzweig et al, 2008 [16]
Pulmonary embolism diagnosis 582 Deitelzweig et al, 2008 [16]
7 days of prophylaxis: enoxaprin (40 mg qd)* 380 Deitelzweig et al, 2008 [16]
7 days of prophylaxis: UFH (5000 IU bid)* 236 Deitelzweig et al, 2008 [16]
*Including $16 in pharmacy and nursing costs assumed per administration.
Bid, twice daily; HIT, heparin-induced thrombocytopenia; IU, international units; qd, once daily; UFH,
unfractionated heparin.
doi:10.1371/journal.pone.0121429.t002
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We used SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) to analyze ENDORSE and
NIS data. We used TreeAge Pro 2009 decision analysis software (TreeAge Software, Williams-
town, MA, USA) to perform the cost-effectiveness analyses.
Results
Of the 68,183 inpatients enrolled in ENDORSE, 9257 were cared for in 81 US hospitals [11]. Of
these patients, 5196 (56.1%) were cared for in medical wards, 2720 (52.3%) and were at ACCP-
defined VTE risk, 1292 (47.5%) of whom received ACCP-recommended prophylaxis [11].
Clinically recognized contraindications to anticoagulant prophylaxis were present in 331
(12.2%) patients at ACCP-defined VTE risk. The proportion of medical inpatients at ACCP-
defined VTE risk for each US hospital ranged from 19.2% to 100% (IQR: 44.8–62.2%).
Based on year 2006 NIS data, 14.3 million medical inpatients aged40 years and discharged
from US acute care hospitals would have met the ENDORSE inclusion criteria. By extrapolat-
ing the ENDORSE findings to this NIS population, we estimated that 7.3 million medical pa-
tients aged40 years would be at ACCP-defined VTE risk in the US acute care setting each
year. Of these, an estimated 3.5 million patients would receive ACCP-recommended VTE pro-
phylaxis and 3.8 million would not (Fig. 1) [11, 13, 15]. After excluding 12.2% of patients esti-
mated to have clinically recognized contraindications to anticoagulants, 3.4 million medical
patients should have received ACCP-recommended anticoagulant prophylaxis.
The results of our cost-effectiveness analysis, including the results from the probabilistic
sensitivity analyses using Monte Carlo simulations, are shown in Table 3. Compared with no
prophylaxis, the LMWH and UFH strategies would be expected to reduce the rates of deaths
by 0.5% and 0.3%, respectively, translating into savings of $50,637 and $25,714 per death
averted in base-case scenario. Applied to our base-case scenario estimate that on an annual
basis there are 3.4 million eligible but unprotected medical patients in US acute care hospitals,
thromboprophylaxis with LMWH or UFH would therefore be estimated to prevent 15,875 or
10,201 deaths annually, with total anticipated savings of $8 million for LMWH and $2.6 mil-
lion, for UFH. Therefore, among medical inpatients at VTE risk who did not receive ACCP-
recommended anticoagulation prophylaxis, each 1% increase in the use of LMWH prophylaxis
would avert 159 deaths and save approximately $8 million dollars each year (Table 4). Alterna-
tively, assuming that UFH was used, each 1% increase in prophylaxis would avert 102 deaths
and save approximately over $2.6 million dollars each year.
One-way sensitivity analyses of key estimates in our decision-tree model indicated that as
long as the probability of developing PE after DVT without treatment is above 14%, both pro-
phylaxis strategies are cost-effective compared with no prophylaxis (Fig. 2A). Second, the prob-
ability of death among PE patients who survived from the critical period immediately after the
acute event increased from 0% to 26% (point-estimate in the decision-tree model); the overall
reduction in death rates ranged from 0.1% to 0.5% for the LMWH strategy, and from 0% to
0.3% for the UFH strategy, compared with no prophylaxis (Fig. 2B). Third, the LMWH strategy
is always dominant (Fig. 2A, B), regardless of the exact value of the two estimates. The Monte
Carlo simulation with 10,000 iterations indicated that: (1) regardless of the cost per death
averted, over 50% of iterations indicated that the LMWH strategy is cost-effective; (2) if the
healthcare system is willing to pay approximately $5,000 per death averted, the UFH strategy
starts to have higher probability of being cost-effective compared with no prophylaxis (Fig. 3).
The annual proportion of medical inpatients at ACCP-defined VTE risk in the US acute
care setting varies among the 81 US ENDORSE hospitals (IQR: 44.8–62.2%). Applying this
variation to the base-case of the decision-tree model, the range of deaths averted each year
would range from 13,927 to 19,336 for a LMWH strategy and from 8949 to 12,425 for a UFH
Cost-Effectiveness of Thromboprophylaxis: Acutely Ill Medical Patients
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strategy; these figures translate to annual total costs saved of between $705 to $979 million for
LMWH, and $230 to $319 million for UFH. For each 1% increase in ACCP-recommended pro-
phylaxis applied to at-risk medical inpatients, the range of annual deaths averted would be 139
to 193 for the LMWH strategy and 89 to 124 for the UFH strategy, with a total estimated sav-
ings of $7 to $9.8 million and $2.3 to $3.2 million, respectively.
Discussion
While a number of studies have suggested that providing anticoagulant prophylaxis to medical
inpatients is highly cost-effective compared with no prophylaxis [16, 17, 56], the present paper
provides new estimates of the magnitude of the opportunity to prevent VTE outcomes
Fig 1. Application of findings from the ENDORSE US population [11, 15] to patients in the 2006 NIS population [13]. aCalculated.
doi:10.1371/journal.pone.0121429.g001
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including attributable deaths in US acute care hospitals by providing prophylaxis to hospital-
ized medical patients at VTE risk, with costs estimated from a US healthcare system perspec-
tive. Moreover, by providing an objective assessment of the proportion of at-risk patients who
have a known contraindication to anticoagulant prophylaxis, we provide an estimate of the sys-
tem-wide impact on both deaths and costs, assuming US hospitals fully implement the revised
2012 ACCP recommendations.
Cost-effectiveness of Thromboprophylaxis in Hospitalized Medical
Inpatients
McGarry et al, in 2004, estimated that the incremental cost in 2001 USD per death averted with
LMWH prophylaxis versus no prophylaxis in acutely ill medical inpatients was $9100, and
LMWH prophylaxis dominated UFH prophylaxis [17]. By contrast, in the present analysis,
Table 3. Cost-effectiveness analysis (2013 US$ among a hypothetical cohort of 10,000 acutely ill medical inpatients at ACCP-defined VTE risk).
Strategy Total cost Deaths Incremental cost* Death averted Cost/death averted ($)*
Base-case
No prophylaxis $13,689,498 1087 – – –
Enoxaparin 40 mg qd $11,309,543 1040 –$2,379,956 47 –$50,637
UFH 5000 IU bid $12,918,092 1057 –$771,407 30 –$25,714
Low (2.5%) cases generated from Monte Carlo simulation (10,000 iterations)§
No prophylaxis $2,774,058 589 – – –
Enoxaparin 40 mg qd $3,282,762 540 $508,704 49 $10,382
UFH 5000 IU bid $4,312,000 555 $1,537,792 34 $45,234
High (97.5%) cases generated from Monte Carlo simulation (10,000 iterations)§
No prophylaxis $50,658,893 1762 – – –
Enoxaparin 40 mg qd $28,887,687 1707 –$21,771,206 55 –$395,840
UFH 5000 IU bid $32,954,385 1722 –$17,704,508 40 –$442,613
*A negative value indicates cost saved.
§ 95% of iterations fall between the low- and high-range.
ACCP, American College of Chest Physicians; bid, twice daily; IU, international units; qd, once daily; UFH, unfractionated heparin; VTE,
venous thromboembolism.
doi:10.1371/journal.pone.0121429.t003
Table 4. Estimated rates and numbers of deaths averted and associated cost savings, with adherence to VTE prophylaxis amongmedical inpa-
tients at VTE risk in US acute care hospitals.
LMWH (Enoxaparin 40 mg qd) vs.
No Prophylaxis
UFH (5000 IU bid) vs. No
Prophylaxis
Rate of deaths averted 0.5% 0.3%
Total deaths averted among medical inpatients at ACCP-deﬁned VTE risk NOT
receiving ACCP-recommended VTE prophylaxis
15,875 10,201
Cost saving per death averted $50,637 $25,714
Total cost saving to prevent all deaths $803,870,748 $262,292,916
VTE-attributable deaths averted for every 1% improvement in adherence to VTE
prophylaxis
159 102
Total cost saving for every 1% improvement in adherence to VTE prophylaxis $8,038,707 $2,622,929
ACCP, American College of Chest Physicians; bid, twice daily; ICER, incremental cost-effectiveness ratio; IU, international units; LMWH, low-molecular-
weight heparin; qd, once daily; UFH, unfractionated heparin; VTE, venous thromboembolism.
doi:10.1371/journal.pone.0121429.t004
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Fig 2. One-way sensitivity analyses to determine the threshold value of (A) the probability of PE after
DVT without treatment; and (B) probability of death among PE patients who survived the period
immediately after the acute event without treatment, among 10,000 acutely ill medical inpatients at
ACCP-defined VTE risk. ACCP, American College of Chest Physicians; bid, twice daily; DVT, deep vein
thrombosis; IU, international units; PE, pulmonary embolism; qd, daily; VTE, venous thromboembolism.
doi:10.1371/journal.pone.0121429.g002
Cost-Effectiveness of Thromboprophylaxis: Acutely Ill Medical Patients
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although our result on the effectiveness of anticoagulant prophylaxis was similar to that re-
ported in the McGarry study, we estimated that provision of VTE prophylaxis to a similar pop-
ulation would produce cost savings in 2013 USD per death averted of over $50K for LMWH
and $25K for UFH. The key difference between the McGarry et al data and our analyses is driv-
en by the cost of US hospital inpatient services, which have increased substantially since 2001
[57]. These included increases in costs related to both the diagnosis of VTE and the treatment
of VTE and of adverse events. In particular, the cost related to treatment of DVT increased
from $3245 to $10,758, and the cost related to PE treatment increased from $8367 to $19,032,
even after adjusting 2001 US$ to 2013 US$ using the medical-care component of the US Con-
sumer Price Index [9, 16, 17]. In the present analysis we estimate that provision of VTE pro-
phylaxis for hospitalized medical patients not only saves lives but also saves dollars from a
healthcare-systems perspective, by avoiding the expenditure of precious resources on the diag-
nosis and treatment of preventable episodes of VTE.
Our findings are similar to a number of other published studies that examined the clinical
and cost-effectiveness of thromboprophylaxis with LMWH and UFH versus placebo in medical
patients [16, 56]. In a paper published in 2008, Deitelzweig et al modeled 2-year outcomes and
costs of prophylaxis in medical inpatients at risk of VTE, finding that an average medical cost
Fig 3. Cost-effectiveness acceptability curve based on a Monte Carlo simulation (10,000 iterations).
bid, twice daily; IU, international units; qd, daily; VTE, venous thromboembolism.
doi:10.1371/journal.pone.0121429.g003
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per patient within 30 days post admission could be reduced by 2006 US$347 by using LMWH
prophylaxis, compared with no prophylaxis, and by 2006 US$89 by using UFH prophylaxis
[16]; both LMWH and UFH prophylaxis would lead to additional savings when this analysis
was extended through 2 years post admission [16]. Extension of this time window beyond 30
days would likely lead to a further reduction in deaths from VTE and to greater cost savings.
Although our analyses provide an estimate of the range of clinical and economic impacts of im-
proving ACCP-recommended VTE prophylaxis in the US hospital care setting annually, the
full impact of the current missed opportunities to provide prophylaxis to at-risk medical pa-
tients may be underestimated. In particular, owing to the aging of the population, increasing
numbers of older patients require hospitalization for a wide variety of acute medical illnesses.
Thus the number of candidates for VTE prevention is rising and may be substantially higher
than previously estimated [58], and the clinical and economic impact of every 1% increase in
adherence to ACCP-recommended VTE prophylaxis may exceed our estimates.
We acknowledge that the uncertainty of the parameter estimates used in the decision-tree
model could influence the study outcome. In particular, the rates of probability of VTE for
each strategy, the probability of developing PE after DVT, and the death rates associated with
PE could have an important effect. The results of our sensitivity analyses and Monte Carlo
simulation indicate that LMWH prophylaxis is a dominant strategy in our model,
primarily due to a lower rate of drug-associated adverse events compared with the UFH strate-
gy and a substantially lower rate of VTE compared with the no-prophylaxis strategy. When
comparing UFH prophylaxis with no prophylaxis, the threshold value of the PE rate after DVT
without treatment was 14%, to be cost-effective, based on the one-way sensitivity analysis. This
is much lower than the estimates reported in other studies [36, 37]. Furthermore, paying US
$5000 per death averted, as illustrated in the acceptability curve based on Monte Carlo simula-
tion, is well below the often-cited threshold of US$50,000 per quality-adjusted life-year
(QALY) gained (assuming each death averted results in a gain of just one QALY) [17]. Lower-
ing the PE-associated mortality rate would not change the direction of our conclusion, as these
changes in absolute rates would occur in the same direction for each of the
strategies compared.
Implications of the Revised 2012 ACCP Recommendations
The 2004 ACCP recommendations, on which these analyses are based, advocate that hospitals
develop standing orders for VTE prophylaxis in broad classes of patients hospitalized with
major medical illness. The recently revised (2012) ACCP guidelines recommend that physi-
cians take an individualized approach to provision of VTE prophylaxis, balancing the benefits
of VTE prevention against bleeding risks in each patient. Comparing 2004 and 2012, there are
no significant differences in the groups of medical patients at risk of VTE that are recom-
mended to receive thromboprophylaxis; however, there are small differences with respect to
the risk of bleeding. Based on the ENDORSE findings in US hospitals, approximately 12% of
patients hospitalized with a severe medical illness have a recognized risk of bleeding sufficient
to preclude the use of anticoagulant prophylaxis. Therefore the potential impact of the 2012
ACCP recommendations-namely that physicians withhold anticoagulant prophylaxis from pa-
tients at known high risk for bleeding-would at most reduce the number of patients who should
receive VTE prophylaxis in the US each year by approximately 12%.
Additional research is needed to estimate the costs and the unknown benefits of mechanical
methods of thromboprophylaxis in the subset of patients who are hospitalized for treatment of
major medical conditions but who cannot receive anticoagulant prophylaxis due to a recog-
nized high risk for bleeding.
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Study Limitations
This study was based on robust US-wide data from the NIS and ENDORSE. Those 81 US EN-
DORSE hospitals were randomly selected from the American Hospital Association database.
The same patient-selection algorithm was used in both NIS and ENDORSE. Consequently, the
findings from the present analysis are highly likely to be generalizable to patients cared for in
US hospitals. Despite the strengths, we recognize a number of potential limitations, including:
uncertainties in our estimates of rates and costs; inclusion of a heterogeneous group of patients
with severe medical illnesses who have a high, but variable, risk of VTE; not accounting for the
longer term consequences of VTE; changes in practice between 2006 and 2013 in terms of im-
proved uptake of current therapies, if any; the extent of adoption of newer prophylactic agents;
and changes in healthcare costs for prevention, diagnosis and treatment of VTE and its associ-
ated complications. However, these cost estimates do provide a benchmark for this setting. In
addition, our decision-tree model is necessarily a simplified representation of VTE and its
management, and does not include all possible strategies and outcomes. Also, the use of US
wholesale prices for medication costs and Medicare reimbursement rates by diagnosis-related
group for treatment costs may not represent the real costs that specific institutions or payers
incur. Individual institutions may negotiate a different purchase price for each medication, and
specific payers may have a different reimbursement rates for each treatment compared with
the payment rates we employed in our model to estimate hospital costs. The introduction of
new classes of treatment, such as direct thrombin inhibitors and factor Xa inhibitors, presents
patients, clinicians and the healthcare system with additional therapeutic choices; however,
none are approved or likely to be approved in the next few years. In addition, many patients
hospitalized for severe medical illnesses will have a limited life expectancy due to the presence
of other, terminal conditions, especially cancer. Further research is needed to quantify the
number of months that VTE prophylaxis delays death in patients who have a poor prognosis,
irrespective of fatal PE, which is a potentially preventable condition.
Supporting Information
S1 Fig. Decision-tree model based on model published by McGarry et al [17], with updated
cost estimates.
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